Biotech Values

[jq1234]

>> without a PBO in phase 3, which would be impossible if FDA gave accelerated approval, we will never learn how well the drug works (or doesnt work).

The widespread assertion that accelerated approval would prevent a placebo controlled ph3 trial had NO basis in reality of past approved ultra orphan indications. Neither approval of Fabrazyme nor Myzoyme prevented subsequent placebo controlled ph3 trials.